Why the study?
Does 4'-epi-doxorubicin improve tolerability and reduce cardiac toxicity compared to doxorubicin in patients with advanced malignancy?
Does 4'-epi-doxorubicin improve tolerability and reduce cardiac toxicity compared to doxorubicin in patients with advanced malignancy?
4'-epi-doxorubicin demonstrates a more favorable toxicity profile, including reduced cardiac damage, and broad antitumor activity compared to doxorubicin in advanced malignancies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bonfante et al. (1982) studied Advanced malignancy (n=108). 4'-epi-doxorubicin (epi-DX) vs. Doxorubicin (DX) was evaluated on Acute toxicity, cardiac toxicity, and antitumor activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: